Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Provectus updates compassionate use program for anticancer candidate PV-10

Nov. 25, 2010

First-in-human data disclosed on dual PI3K/mTOR inhibitors PF-05212384 and PF-04691502

Nov. 24, 2010

Boehringer Ingelheim describes novel mTOR inhibitors

Nov. 24, 2010

Nerviano Medical Sciences claims new HSP 90 inhibitors

Nov. 23, 2010

U.S. DoD recommends funding development of STA-9584 for prostate cancer

Nov. 23, 2010

D-3263 HCl may stabilize disease in patients with advanced prostate cancer

Nov. 23, 2010

University of Michigan describes new 1,4-benzodiazepinone derivatives

Nov. 22, 2010

Immunovaccine's phase I/II DPX-Survivac testing will target ovarian cancer

Nov. 22, 2010

Spanish scientists present new inhibitors of PI3K/mTOR

Nov. 22, 2010

New HIF-1-alpha inhibitor P-2630 demonstrates oncolytic activity in vivo

Nov. 22, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....